French
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
Overview of attention for article published in BMJ Open, February 2020
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (91st percentile)
-
High Attention Score compared to outputs of the same age and source (87th percentile)
Readers on
- mendeley
- 86 Mendeley